RESUMO
According to the heterogenous nature of hemolytic uremic syndrome in relation to the etiology, pathophysiology, treatment and diagnosis, we wish to draw attention to the main characteristics about its epidemiological clinical and immunopathological aspects. The HUS's distributes through all the world, but in Argentina, North of Europe, South Africa and west of USA the incidence is higher than the rest of the countries. The immunopathological studies shows thrombotic angiopathic lesion, consisting in generalized alteration of the capillary and arteriolar epithelium. Decreased levels of PGI2, Von Willebrand's factor and bacterial toxins are apparently involved among mechanism that are able to produce HUS. Dialysis is one of the main helps in the treatment of HUS, and in spite of our continued advances in knowledge about this disease, still further developments are needed in pathophysiology and therapeutics to enlight its intimate mechanisms.
Assuntos
Síndrome Hemolítico-Urêmica , Síndrome Hemolítico-Urêmica/diagnóstico , Síndrome Hemolítico-Urêmica/etiologia , Síndrome Hemolítico-Urêmica/fisiopatologia , Síndrome Hemolítico-Urêmica/terapiaRESUMO
Ninety-six newborn infants with seizures were scored during the initial hospitalization on abnormality of EEG, neurologic examination, etiology of seizures, length of seizure, type of seizure, and birth weight under or over 1,500 gm. At 3 months, corrected for gestational age, the 80 surviving infants were scored on abnormality of current EEG, neurologic examination, etiology of seizure, presence or absence of seizure since hospital discharge, and birth weight under or over 1,500 gm. At age 10 months, 76 of 77 surviving infants were evaluated with the Gesell Developmental Inventory, physical examination, and neurologic examination. Chi square analysis documented that the scoring system was an accurate predictor of those infants with seizure disorders, mental retardation, and motor dysfunction. The score may assist the clinician in making decisions in regard to anticonvulsant therapy during initial hospitalization or at age 3 months.